LXEO - Lexeo Therapeutics, Inc.

7.2
-0.240   -3.333%

Share volume: 1,431,602
Last Updated: 03-10-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.03%

PREVIOUS CLOSE
CHG
CHG%
$7.44
-0.24
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
33%
Profitability 35%
Dept financing 23%
Liquidity 50%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
5.11%
1 Month
6.04%
3 Months
-26.53%
6 Months
39.00%
1 Year
170.68%
2 Year
-50.31%
Key data
Stock price
$7.20
P/E Ratio 
0.00
DAY RANGE
$7.04 - $7.65
EPS 
-$3.00
52 WEEK RANGE
$1.45 - $10.99
52 WEEK CHANGE
$147.42
MARKET CAP 
358.568 M
YIELD 
N/A
SHARES OUTSTANDING 
72.987 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
2.09
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,016,831
AVERAGE 30 VOLUME 
$762,293
Company detail
CEO: R. Nolan Townsend
Region: US
Website: www.lexeotx.com
Employees: 0
IPO year: 2023
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

We are a clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Our principal executive offices are located at 345 Park Avenue South, Floor 6, New York, New York.

Recent news